Sheba Personalized CAR-T Immunotherapy Program for Blood Cancers
O que está incluído neste pacote
Procedimentos médicos
- Terapia com células T CAR
- Serviços de enfermagem 24 horas
- 3 refeições por dia pelo nutricionista
- Consulta com um onco-hematologista
Duração
- 21 dias no hospital
- 7 dias no hotel
Acomodação
Hospitalização
Transporte
Transfer aeroporto-clínica-aeroporto
Informações adicionais
CAR-T Therapy at Sheba Medical Center
Sheba Medical Center is a global leader in CAR-T cell therapy, offering advanced, personalized treatment for a wide range of hematologic cancers, including:
Non-Hodgkin lymphomas (DLBCL, FL, MCL), primary CNS lymphoma, ALL, CLL/Richter’s transformation, Burkitt lymphoma, and multiple myeloma.
A Fast, Fully Integrated CAR-T Process
At Sheba, the entire CAR-T procedure is performed on-site, ensuring speed, precision, and optimal cell quality.
The process includes three key steps:
Apheresis – collection of the patient’s T-cells
Cell Engineering – genetic modification at the Advanced Biotherapy Center
Infusion – reintroduction of modified cells to target cancer
Unlike many centers, Sheba does not send cells abroad. This allows treatment to be completed in approximately 10 days, making CAR-T a true “living drug” capable of long-term remission.
All patients are evaluated and treated under the supervision of Prof. Arnon Nagler, a global leading expert in hemato-oncology.
Why Choose Sheba for CAR-T
Rapid access – on-site production reduces waiting time from weeks to ~10 days
Extensive experience – largest CAR-T program in Israel and the region
Dedicated CAR-T units – for both adults and children, with 24/7 monitoring
Multidisciplinary care – hematology, oncology, immunology experts working together
Global patient services – full support with medical coordination and travel logistics
Clinical Excellence & Outcomes
Sheba is a global leader in pediatric CAR-T, with no strict age limitations for pediatric patients. Reported outcomes show:
~90% remission in pediatric patients
~80% in young adults (up to 23 years)
~70% in adults
Comprehensive Evaluation & Support
Each patient undergoes a thorough diagnostic work-up, including:
physician consultations, advanced imaging (CT, ultrasound, nuclear medicine), bone marrow biopsy, genetic and molecular testing (FISH, karyotyping), cardiac and pulmonary evaluation, and laboratory testing.
Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients.
Key Advantage
By combining in-house cell manufacturing, leading expertise, and integrated care, Sheba delivers one of the fastest, most advanced, and most personalized CAR-T programs in the world.
Assistência Bookimed 24/7
- Coordenador médico pessoal
- Arranjos de viagem médica — reserva de passagens aéreas e quartos de hotel com preços especiais de parceiros
- Defesa do paciente durante a viagem médica
Preço do programa
O que NÃO está incluído neste pacote
Médico
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Como estamos indo?
Sobre a clínica
A terapia com células CAR-T no Sheba Medical Center em Tel Aviv, Israel, pode custar cerca de US$ 63.100 pelo programa completo. O hospital está entre os 10 melhores do mundo e oferece este tratamento avançado sob a coordenação do Prof. Arnon Nagler, um renomado especialista em transplante de medula óssea.
Sobre o Tratamento
A terapia com células CAR-T é uma abordagem inovadora para leucemia, linfoma e mieloma múltiplo. O processo envolve a coleta das células T do paciente, sua modificação genética em laboratório e a reinfusão após a quimioterapia. O procedimento exige 21 dias de internação hospitalar, com possibilidade de permanência na UTI.
O que está incluído
- Avaliação abrangente (US$ 5.000 - US$ 10.000)
- Coleta de células via aférese (US$ 6.600)
- Preparação laboratorial das células modificadas (US$ 20.000)
- Quimioterapia de condicionamento (US$ 5.000)
- Internação de 21 dias (US$ 31.500)
- Avaliação pós-tratamento (US$ 3.000 - US$ 5.000)
Preparação e Recuperação
Os pacientes necessitam de biópsia de medula óssea, exames de PET/CT e exames de sangue antes do tratamento. Após a infusão, ocorre o monitoramento diário para a síndrome de liberação de citocinas. A permanência total recomendada em Israel é de 4 a 6 semanas. Vale ressaltar que o CAR-T para mieloma ainda é experimental.
O Sheba Medical Center atende 1,5 milhão de pacientes anualmente e oferece atendimento multilíngue. É necessário um depósito de US$ 50.000 a US$ 60.000 antes da chegada. Entre em contato com o hospital para avaliar se esta terapia é adequada para o seu caso.
Pagamento e Recompensas
Não pague por nossos serviços
Efetue o pagamento diretamente na clínica ou na conta bancária oficial dela.
Algumas clínicas podem exigir um depósito como parte de sua política.
Divida seus pagamentos com opções de parcelamento.
Ganhe recompensas por indicar amigos ao Bookimed.